Inicio
Detalle del título uniforme
Hematology/Oncology and Stem Cell Therapy
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (2)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaFever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide / Marcos Arango Barrientos ; Juan Felipe Combariza Vallejo
Título : Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide Tipo de documento : documento electrónico Autores : Marcos Arango Barrientos, ; Juan Felipe Combariza Vallejo, Fecha de publicación : 2017 Títulos uniformes : Hematology/Oncology and Stem Cell Therapy Idioma : Inglés (eng) Palabras clave : Cyclophosphamide fever haploidentical hematopoietic stem cell transplantation peripheral blood stem cell transplantation prognosis Resumen : Objective/background: Noninfection-related fever can occur after peripheral blood stem cell infusion in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. The objective of this study was to analyze the incidence of fever and characterize some clinical features of affected patients. Methods: A retrospective case-series study with 40 patients who received haploidentical hematopoietic stem cell transplantation was carried out. Results Thirty-three patients (82.5%) developed fever; no baseline characteristic was associated with its development. Median time to fever onset was 25.5 h (range, 9.5–100 h) and median peak temperature was 39.0 °C (range, 38.1–40.5 °C). Not a single patient developed hemodynamic or respiratory compromise that required admission to the intensive care unit. Fever was not explained by infection in any case. Ninety-one percent of the febrile episodes resolved within 96 h of cyclophosphamide administration. No significant difference in overall survival, event-free survival, or graft versus host disease-free/relapse-free survival was found in the group of febrile individuals after peripheral blood stem cell infusion. Conclusion: Fever after peripheral blood stem cell infusion in this clinical setting was common; it usually subsides with cyclophosphamide administration. The development of fever was not associated with an adverse prognosis. Mención de responsabilidad : Marcos Arango, Juan F Combariza Referencia : Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):79-84. DOI (Digital Object Identifier) : 10.1016/j.hemonc.2017.03.001 PMID : 28390959 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1658-3876(17)30031-6 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4047 Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide [documento electrónico] / Marcos Arango Barrientos, ; Juan Felipe Combariza Vallejo, . - 2017.
Obra : Hematology/Oncology and Stem Cell Therapy
Idioma : Inglés (eng)
Palabras clave : Cyclophosphamide fever haploidentical hematopoietic stem cell transplantation peripheral blood stem cell transplantation prognosis Resumen : Objective/background: Noninfection-related fever can occur after peripheral blood stem cell infusion in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. The objective of this study was to analyze the incidence of fever and characterize some clinical features of affected patients. Methods: A retrospective case-series study with 40 patients who received haploidentical hematopoietic stem cell transplantation was carried out. Results Thirty-three patients (82.5%) developed fever; no baseline characteristic was associated with its development. Median time to fever onset was 25.5 h (range, 9.5–100 h) and median peak temperature was 39.0 °C (range, 38.1–40.5 °C). Not a single patient developed hemodynamic or respiratory compromise that required admission to the intensive care unit. Fever was not explained by infection in any case. Ninety-one percent of the febrile episodes resolved within 96 h of cyclophosphamide administration. No significant difference in overall survival, event-free survival, or graft versus host disease-free/relapse-free survival was found in the group of febrile individuals after peripheral blood stem cell infusion. Conclusion: Fever after peripheral blood stem cell infusion in this clinical setting was common; it usually subsides with cyclophosphamide administration. The development of fever was not associated with an adverse prognosis. Mención de responsabilidad : Marcos Arango, Juan F Combariza Referencia : Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):79-84. DOI (Digital Object Identifier) : 10.1016/j.hemonc.2017.03.001 PMID : 28390959 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1658-3876(17)30031-6 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4047 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000645 AC-2017-034 Archivo digital Producción Científica Artículos científicos Disponible
Título : Catheter insertion site plasmacytoma Tipo de documento : documento electrónico Autores : Marcos Arango Barrientos, ; Carolina Echeverri Jaramillo, Fecha de publicación : 2016 Títulos uniformes : Hematology/Oncology and Stem Cell Therapy Idioma : Inglés (eng) Mención de responsabilidad : Marcos Arango, Carolina Echeverri Referencia : Hematol Oncol Stem Cell Ther. 2016 Mar;9(1):34-5. DOI (Digital Object Identifier) : 10.1016/j.hemonc.2015.07.003 PMID : 26276079 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1658-3876(15)00079-5 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3998 Catheter insertion site plasmacytoma [documento electrónico] / Marcos Arango Barrientos, ; Carolina Echeverri Jaramillo, . - 2016.
Obra : Hematology/Oncology and Stem Cell Therapy
Idioma : Inglés (eng)
Mención de responsabilidad : Marcos Arango, Carolina Echeverri Referencia : Hematol Oncol Stem Cell Ther. 2016 Mar;9(1):34-5. DOI (Digital Object Identifier) : 10.1016/j.hemonc.2015.07.003 PMID : 26276079 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1658-3876(15)00079-5 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3998 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000592 AC-2016-067 Archivo digital Producción Científica Artículos científicos Disponible
